Why 2025 Is the Turning Point for Avian Powassan Virus Diagnostics: Unprecedented Growth, Cutting-Edge Tech, and Industry Leaders Set the Stage for a Safer Future

• Executive Summary: The State of Avian Powassan Virus Diagnostics in 2025
• Key Market Drivers and Restraints in Avian Powassan Virus Testing
• Breakthrough Diagnostic Technologies: From qPCR to Next-Gen Sequencing
• Leading Players and Strategic Initiatives (Official Sources Only)
• Regulatory Trends and Compliance Landscape (2025–2030 Outlook)
• Market Size, Share, and Forecast Through 2030
• Emerging Applications: Surveillance, Epidemiology, and Wildlife Health
• Regional Analysis: Hotspots and Growth Opportunities Worldwide
• Investment, M&A, and Partnership Activity
• Future Outlook: Innovations and Disruptive Trends Shaping the Next 5 Years
• Sources & References

Executive Summary: The State of Avian Powassan Virus Diagnostics in 2025

As of 2025, diagnostics for avian Powassan virus (POWV) are at a pivotal stage, shaped by an escalating awareness of tick-borne flaviviruses in avian populations and their potential implications for both animal and human health. The Powassan virus, historically associated with North American ticks and mammalian hosts, has gained renewed attention due to the expanding geographic range of vector species and emerging evidence of infection in wild and domestic birds. This shift has catalyzed research and development in avian POWV diagnostics, with a focus on early detection, surveillance, and differentiation from closely related flaviviruses.

Currently, diagnostic strategies rely on a combination of molecular assays—primarily reverse transcription polymerase chain reaction (RT-PCR)—and serological tests such as enzyme-linked immunosorbent assays (ELISA) tailored for avian samples. Leading global suppliers of molecular and serological diagnostic reagents such as Thermo Fisher Scientific, QIAGEN, and Promega Corporation have expanded their portfolios to include reagents and kits validated for flavivirus detection, facilitating the adaptation of protocols for POWV in avian species. These advancements are underpinned by collaborative efforts between public health agencies and veterinary research institutes to standardize testing and improve sensitivity and specificity.

A major milestone in 2024 was the introduction of multiplex PCR platforms capable of simultaneous detection of POWV and other tick-borne pathogens in avian blood and tissue samples. Companies like Bio-Rad Laboratories and Roche have launched high-throughput systems increasingly adopted by diagnostic laboratories and wildlife surveillance programs. These tools are particularly valuable in regions witnessing rapid tick range expansion due to climate change, notably the northeastern and upper midwestern United States. Early data from field deployments indicate a significant increase in the detection rates of POWV in migratory and resident bird species, highlighting the utility of next-generation diagnostics for real-time epidemiological assessments.

Looking ahead, the sector anticipates further integration of point-of-care (POC) technologies, including portable isothermal amplification devices and rapid serological lateral flow assays. Companies such as Abbott are investing in miniaturized platforms for field use, which could revolutionize avian disease surveillance by enabling immediate, on-site diagnosis. Additionally, partnerships between diagnostic manufacturers and wildlife agencies are expected to drive the development of avian-specific test validation and cross-reactivity studies, addressing current challenges in distinguishing POWV from other flaviviruses.

In summary, avian Powassan virus diagnostics in 2025 are characterized by increasing technological sophistication, broader accessibility of advanced molecular and serological tools, and a growing recognition of the role of birds in the POWV transmission cycle. The outlook for the next several years is marked by ongoing innovation and cross-sector collaboration, with a goal of strengthening early detection and response capabilities amid evolving ecological and epidemiological landscapes.

Key Market Drivers and Restraints in Avian Powassan Virus Testing

The market for Avian Powassan Virus (POWV) diagnostics in 2025 is shaped by a complex interplay of accelerating drivers and persistent restraints, each influencing the adoption and development of diagnostic solutions. Several pivotal factors are contributing to market growth, while challenges continue to temper the sector’s expansion.

Key Market Drivers

• Emergence and Spread of Powassan Virus: The increased incidence and geographic spread of tick-borne diseases, including Powassan virus, in North America and parts of Europe are heightening demand for advanced diagnostics. Surveillance data from organizations such as the Centers for Disease Control and Prevention highlight a rising threat, particularly among avian populations that can act as reservoirs or vectors.
• Advancements in Molecular Diagnostic Technologies: Continued innovation in molecular diagnostics—such as real-time PCR and next-generation sequencing—by leading manufacturers is enhancing sensitivity and specificity for avian POWV detection. Companies like Thermo Fisher Scientific and QIAGEN are at the forefront, offering PCR reagents, instruments, and workflow solutions that are increasingly tailored for veterinary and wildlife surveillance applications.
• Government and Institutional Investments: Funding initiatives from governmental and international agencies are supporting research, surveillance, and diagnostic infrastructure. The push for “One Health” approaches—integrating human, animal, and environmental health—further incentivizes the development of robust avian viral diagnostic platforms.
• Expansion of Veterinary Diagnostic Networks: Growth in centralized and field-deployable veterinary diagnostic laboratories, underpinned by organizations like IDEXX Laboratories, is improving access to rapid avian virus testing, particularly in regions prone to tick-borne diseases.

Key Market Restraints

• Lack of Commercially Available, Avian-Specific POWV Assays: As of 2025, there remains a limited portfolio of validated, commercially available assays specifically for avian Powassan virus detection. Most available kits are adapted from human or general veterinary tick-borne pathogen panels, leading to potential sensitivity and specificity gaps.
• Regulatory and Validation Challenges: Diagnostic products for emerging viruses in wildlife face protracted regulatory approval and technical validation timelines. This is particularly true in jurisdictions with stringent requirements for veterinary diagnostics, such as the EU. Companies are required to demonstrate both analytical and clinical performance, which can delay product launches.
• Limited Awareness and Testing Infrastructure in High-Risk Regions: Many regions with rising tick populations and avian hosts lack the veterinary diagnostic infrastructure and trained personnel required for routine POWV surveillance. This infrastructure gap is especially pronounced outside North America and Western Europe.
• Economic Constraints: Budget limitations in public and private veterinary sectors can restrict adoption of advanced molecular diagnostics, particularly in low- and middle-income countries where investment in wildlife disease surveillance is less prioritized.

Looking ahead, the outlook for avian Powassan virus diagnostics through the next several years will depend on both the pace of assay development by industry leaders and the expansion of supportive policy and funding frameworks. Innovations from global life sciences companies and increasing recognition of zoonotic risks in wildlife are set to gradually overcome current restraints, enabling broader adoption and improved disease management.

Breakthrough Diagnostic Technologies: From qPCR to Next-Gen Sequencing

Avian Powassan virus (POWV), an emerging tick-borne flavivirus with zoonotic potential, has prompted intensified efforts in diagnostic technology development, especially as avian species are increasingly recognized as potential reservoirs or amplifying hosts. In 2025, the diagnostic landscape for avian POWV detection is defined by both incremental improvements in established molecular platforms and the introduction of advanced, high-throughput technologies.

Quantitative polymerase chain reaction (qPCR) remains the cornerstone of avian POWV diagnostics. qPCR offers rapid, sensitive, and specific viral RNA detection directly from avian tissue, blood, or tick vectors collected from birds. Leading providers of real-time PCR instrumentation and reagents, such as Thermo Fisher Scientific and Bio-Rad Laboratories, continue to support laboratories with validated kits and platforms, now increasingly optimized for multiplexing. The trend toward automation, with instruments capable of processing hundreds of samples per run, addresses the growing need for large-scale avian surveillance as climate-driven tick range expansion raises concern for POWV spread.

Recent years have seen next-generation sequencing (NGS) emerge as a transformative tool for avian POWV diagnostics. NGS enables not only unbiased detection of POWV in complex avian samples but also supports phylogenetic analysis, outbreak source tracing, and the discovery of novel viral strains. In 2025, benchtop sequencers from companies such as Illumina and Oxford Nanopore Technologies are increasingly accessible to veterinary and public health laboratories. Their platforms allow for simultaneous surveillance of POWV and co-circulating pathogens, offering a comprehensive picture of avian viral ecology. Several pilot programs are underway in North America, integrating NGS into wildlife surveillance networks to monitor viral evolution and potential zoonotic spillover events.

Looking forward, the integration of point-of-care (POC) molecular diagnostics is anticipated to further revolutionize avian POWV surveillance. Portable PCR instruments and isothermal amplification platforms, championed by firms like Cepheid and Abbott, are being adapted for field use, allowing for rapid, on-site testing of avian populations and ticks. While these technologies are currently in early adoption for avian pathogens, cost reductions and improved assay specificity are expected over the next few years, broadening their deployment.

In summary, 2025 marks a period of significant advancement in avian Powassan virus diagnostics, driven by robust qPCR platforms, the expanding role of NGS, and the promise of portable POC devices. Ongoing collaborations between industry leaders and research networks will continue to shape the future of avian viral disease detection and response.

Leading Players and Strategic Initiatives (Official Sources Only)

The landscape for avian Powassan virus (POWV) diagnostics is rapidly evolving in 2025, as emerging threats from zoonotic and vector-borne viruses drive investment and innovation. Though Powassan virus is primarily associated with tickborne encephalitis in North America, avian surveillance is increasingly recognized as a critical component of early detection and outbreak prevention. Leading industry players and public health organizations are taking strategic steps to develop, validate, and deploy sensitive diagnostics tailored for avian hosts.

Among the leading companies, Thermo Fisher Scientific has expanded its molecular diagnostic portfolio to include custom real-time PCR assays adaptable for avian sample matrices. Their platforms enable high-throughput screening, a necessity for wildlife and migratory bird monitoring programs. Bio-Rad Laboratories continues to provide reagents and instruments for nucleic acid extraction and qPCR, and is actively collaborating with public health agencies to validate multiplex panels for arbovirus detection, including POWV.

Major suppliers such as QIAGEN have also positioned themselves as key facilitators of avian virus diagnostics. QIAGEN’s sample preparation kits and automated systems are widely used in veterinary reference laboratories, supporting the rapid turnaround required for field-collected avian specimens. These technologies are being integrated with next-generation sequencing (NGS) workflows for broader pathogen surveillance, further enabling the detection of POWV and related flaviviruses.

On the organizational front, the Centers for Disease Control and Prevention (CDC) and the World Organisation for Animal Health (WOAH, formerly OIE) are driving collaborative initiatives with diagnostic manufacturers and academic labs to harmonize testing protocols. Their strategic focus includes proficiency testing, the development of reference reagents, and surveillance networks that integrate avian data with broader epidemiological monitoring.

Looking ahead, leading players are expected to invest in digital PCR, portable point-of-care devices, and AI-enhanced data analytics to improve the sensitivity, speed, and accessibility of avian POWV diagnostics. Strategic partnerships between industry and government will likely intensify, supporting preparedness against emerging zoonoses. Companies with global footprints, such as Thermo Fisher Scientific and QIAGEN, are uniquely positioned to scale these innovations across North America and regions at risk of POWV expansion, as climate and ecological changes alter the habitats of avian hosts and tick vectors.

Regulatory Trends and Compliance Landscape (2025–2030 Outlook)

The regulatory landscape for avian Powassan virus diagnostics is rapidly evolving as concerns mount over emerging zoonotic threats and the need for robust surveillance in both wildlife and poultry sectors. As of 2025, regulatory agencies in North America, Europe, and Asia-Pacific are intensifying their focus on diagnostics capable of early and precise detection of Powassan virus lineages in avian populations, reflecting a broader commitment to One Health strategies that bridge animal and human health.

The U.S. Food and Drug Administration (FDA) plays a central role in shaping the compliance framework for molecular and serological diagnostic assays under its medical devices and veterinary products regulations. Recent guidance emphasizes expedited review pathways for high-priority zoonotic agents and alignment with the U.S. Department of Agriculture (USDA) for tests intended for animal surveillance programs. Parallel efforts in Canada, coordinated through the Canadian Food Inspection Agency, are updating regulatory requirements for veterinary diagnostics to ensure rapid market entry for novel platforms targeting Powassan and related arboviruses.

In the European Union, the European Medicines Agency (EMA) and the European Food Safety Authority (EFSA) are collaborating to harmonize standards for avian viral diagnostics, particularly in the context of transboundary disease control and wildlife monitoring. The EU In Vitro Diagnostic Regulation (IVDR), fully enforced since 2022, sets stringent demands for performance validation, traceability, and post-market surveillance—requirements expected to shape product development and regulatory submissions through 2030.

Diagnostic manufacturers such as QIAGEN and Thermo Fisher Scientific—both global leaders in molecular and immunodiagnostic technologies—are actively engaging with regulators to align their avian Powassan virus test development pipelines with these evolving standards. These companies are ramping up investments in automation, digital reporting, and multiplex assay formats to facilitate compliance and streamline approvals across major jurisdictions. Meanwhile, suppliers like Bio-Rad Laboratories are focusing on quality management systems and external proficiency testing, anticipating stricter post-market performance monitoring requirements.

Looking ahead to 2030, regulatory trends point toward increased demand for cross-border data sharing, digital traceability, and real-time surveillance integration. Compliance frameworks are likely to require robust interoperability with national and international disease databases, necessitating ongoing collaboration between diagnostic developers, regulatory authorities, and public health agencies. The ongoing evolution of the regulatory landscape will thus shape innovation, commercialization timelines, and the global response capacity to avian Powassan virus threats in the years ahead.

Market Size, Share, and Forecast Through 2030

The global market for avian Powassan virus diagnostics is emerging as a distinct segment within the broader vector-borne disease diagnostics sector. As of 2025, the market remains nascent due to the relatively low incidence and emerging recognition of Powassan virus infections in avian reservoirs. However, ongoing concerns about zoonotic spillover and the potential role of birds in viral ecology are driving increased surveillance measures, particularly in North America and parts of Eurasia. While precise market size figures are limited due to the specialized nature of avian Powassan testing, the segment is expected to experience a moderate compound annual growth rate (CAGR) through 2030.

Key diagnostics currently in use include ELISA kits, RT-PCR assays, and serological tests, many of which are adapted from those developed for human and mammalian Powassan virus detection. Major global suppliers in the broader arbovirus diagnostics market, such as Thermo Fisher Scientific and Abbott, are expanding their research portfolios to address emerging zoonotic threats, including avian reservoirs. These companies provide laboratory reagents, PCR platforms, and immunoassay products that can be customized for avian sample testing, though dedicated avian Powassan-specific products remain in early-stage development.

In 2025, North America is anticipated to hold the largest share of the avian Powassan virus diagnostics market, owing to heightened public health preparedness and active monitoring programs led by agencies such as the Centers for Disease Control and Prevention and wildlife health organizations. Europe is also witnessing increased interest, particularly in regions with expanding tick populations and migratory bird corridors. Collaborative surveillance projects involving universities, public health labs, and veterinary diagnostic companies are fueling demand for robust, scalable testing solutions.

Looking ahead to 2030, the avian Powassan virus diagnostics market is forecast to grow at a steady pace, driven by several factors:

• Rising funding for wildlife pathogen surveillance and One Health initiatives.
• Technological advancements in multiplex PCR and next-generation sequencing, with key input from companies like Illumina and Bio-Rad Laboratories.
• Expanded adoption of portable and field-deployable diagnostic systems for rapid avian sample analysis.
• Regulatory encouragement for early detection and monitoring of zoonotic viruses in avian populations.

While the avian Powassan virus diagnostics segment will likely remain niche compared to diagnostics for more prevalent avian or tick-borne diseases, its importance is expected to grow as part of integrated biosurveillance frameworks. By 2030, market share is projected to broaden in response to global health security priorities and the ongoing evolution of pathogen detection technologies.

Emerging Applications: Surveillance, Epidemiology, and Wildlife Health

In 2025, the emergence of Powassan virus (POWV) as a significant zoonotic threat is driving rapid advancements in avian diagnostic technologies, with a focus on surveillance, epidemiology, and wildlife health. Avian hosts, particularly migratory birds, are increasingly recognized as potential reservoirs or amplifiers of POWV, necessitating robust diagnostics to monitor virus circulation and inform public health interventions.

Recent years have seen the adaptation of molecular and serological assays, originally developed for human or tick samples, to avian matrices. Companies specializing in veterinary diagnostics, such as Zoetis and IDEXX Laboratories, have expanded their platforms to facilitate high-throughput RT-PCR and ELISA testing for flaviviruses, including protocols adaptable for avian samples. In parallel, manufacturers like Thermo Fisher Scientific continue to supply reagents and instruments widely used by wildlife surveillance programs across North America. These platforms support both targeted POWV testing and broader flavivirus screening, leveraging multiplex capabilities to differentiate POWV from closely related agents such as West Nile virus.

On the epidemiological front, coordinated surveillance efforts have intensified. National and regional wildlife agencies, in partnership with academic labs, are deploying these diagnostics to monitor wild bird populations in potential POWV endemic areas. The United States Geological Survey’s National Wildlife Health Center, for example, utilizes standardized molecular tools to track arboviral activity in avian hosts. As of 2025, data-sharing platforms are evolving to integrate molecular results with geospatial and ecological metadata, providing actionable insights for both wildlife and public health authorities.

Looking ahead, the next several years are expected to bring further innovation. Industry leaders are investing in rapid, field-deployable diagnostics tailored for remote wildlife sampling. Portable PCR devices, immunochromatographic strips, and next-generation sequencing workflows are in advanced development, with field trials anticipated by 2026. Companies such as Bio-Rad Laboratories and QIAGEN are leading evaluations of point-of-care nucleic acid detection systems that may soon be validated for avian surveillance applications.

In summary, the drive to better understand avian involvement in POWV ecology is catalyzing both the refinement of existing diagnostics and the development of novel tools. The combined efforts of diagnostic manufacturers and wildlife health organizations are positioning the sector to respond rapidly to emerging threats, with the promise of enhanced early warning systems and improved risk assessment for both animals and humans over the next few years.

Regional Analysis: Hotspots and Growth Opportunities Worldwide

The regional landscape for Avian Powassan Virus diagnostics in 2025 is shaped by both epidemiological trends and the maturation of diagnostic technologies. Although Powassan Virus (POWV) is primarily known as a tick-borne flavivirus affecting humans and small mammals in North America, recent concerns about its detection in avian populations have prompted increased surveillance and research, particularly in regions with high tick density and migratory bird activity.

North America remains the epicenter of Powassan Virus research and diagnostics, given the established presence of the virus in endemic tick populations across the northeastern United States and eastern Canada. The region benefits from a robust public health infrastructure and established reference laboratories, such as those operated by the Centers for Disease Control and Prevention and Public Health Agency of Canada. Leading companies like Thermo Fisher Scientific and Bio-Rad Laboratories supply molecular and serological assay platforms, which are increasingly being adapted for wildlife and avian testing. In 2025, regional health agencies are expected to increase surveillance in migratory bird pathways, particularly in the Atlantic and Mississippi flyways, to better understand avian involvement in POWV transmission cycles.

Europe is an emerging area of interest due to the presence of related tick-borne flaviviruses (such as Tick-Borne Encephalitis Virus) and the migratory linkage with North America. Diagnostic infrastructure in the European Union is highly developed, with organizations like the European Centre for Disease Prevention and Control supporting coordinated surveillance and response. Companies such as QIAGEN are well-positioned to adapt their molecular diagnostic kits for avian and wildlife surveillance in response to potential POWV incursions.

Asia-Pacific currently reports no endemic POWV activity, but regional diagnostics markets—particularly in Japan, China, and Australia—are closely monitoring developments due to the high volume of migratory birds crossing the northern Pacific. Leading diagnostics manufacturers including Sysmex Corporation and FUJIFILM Holdings possess the technological capacity to rapidly respond should surveillance indicate a threat.

• Growth opportunities exist in the development of rapid, field-deployable diagnostics for wildlife and avian samples, especially in North America and Europe.
• Collaborative surveillance networks and cross-border research initiatives are accelerating, driven by organizations such as the World Organisation for Animal Health.
• Investment in next-generation sequencing and multiplex PCR platforms is expected to rise, enabling more sensitive detection of POWV in diverse avian hosts.

Overall, while North America leads in both case burden and diagnostic innovation, Europe and Asia-Pacific are strategically investing in preparedness and surveillance, positioning themselves as key regions for growth in avian Powassan Virus diagnostics through 2025 and beyond.

Investment, M&A, and Partnership Activity

The avian Powassan virus diagnostics sector is beginning to attract heightened attention from investors, major life sciences firms, and diagnostic technology developers as vector-borne viral threats expand and surveillance needs increase globally. In 2025, investment in this niche, while currently modest compared to broader virology diagnostics, is experiencing strategic growth driven by concerns about zoonotic transmission and avian reservoir monitoring. Several notable trends and activities are shaping the landscape.

• Strategic Partnerships: Diagnostic leaders with established expertise in arbovirus detection, such as Thermo Fisher Scientific and F. Hoffmann-La Roche Ltd, are forming collaborations with academic research centers and public health agencies. These alliances focus on adapting existing PCR and serological platforms for rapid avian Powassan virus detection, leveraging proprietary assay development and automated workflow capabilities.
• Targeted M&A Activity: While no blockbuster acquisitions directly tied to avian Powassan virus diagnostics have been publicly disclosed as of 2025, several midsize molecular diagnostics innovators specializing in vector-borne disease panels have been approached by larger diagnostics conglomerates. Companies such as Bio-Rad Laboratories and QIAGEN have a history of acquiring niche assay developers and may pursue similar strategies as the avian Powassan virus market segment matures and surveillance funding increases.
• Investment and Grant Funding: There is a marked increase in public and private grant funding for diagnostic innovation targeting emerging tick- and mosquito-borne viruses in birds. Organizations like the Centers for Disease Control and Prevention and national agricultural agencies are supporting consortia to validate and deploy field diagnostics, often in partnership with diagnostics manufacturers for pilot projects and product co-development.
• Industry Outlook: Over the next few years, as cross-sectoral One Health initiatives expand and regulatory pathways for emergency-use diagnostics become more defined, market entrants are expected to accelerate. This will likely fuel additional venture capital inflows and spark further M&A and partnership activity, especially if avian reservoirs for Powassan virus are implicated in broader outbreaks or surveillance programs identify significant interspecies transmission threats.

While the avian Powassan virus diagnostics market in 2025 remains emergent, the sector is poised for continued growth, driven by interdisciplinary collaborations and the increasing prioritization of zoonotic disease preparedness by both public and private actors.

Future Outlook: Innovations and Disruptive Trends Shaping the Next 5 Years

The landscape for Avian Powassan Virus (POWV) diagnostics is poised for significant transformation over the next five years, driven by advances in molecular techniques, digital platforms, and the evolving needs of avian health surveillance. As 2025 unfolds, intensified concerns over zoonotic spillover and cross-species virus adaptation are accelerating both public and private sector investments in rapid, field-deployable diagnostics tailored to avian hosts.

One of the primary trends is the miniaturization and automation of molecular diagnostic platforms. Companies such as Bio-Rad Laboratories and Thermo Fisher Scientific are expanding their portfolios of portable PCR and isothermal amplification systems, with increasing focus on multiplexing—allowing simultaneous detection of POWV alongside other arboviruses in wild and domestic birds. These instruments are expected to become more robust against environmental variables, supporting reliable on-site testing in remote field conditions where avian surveillance is critical.

Another disruptive innovation arises from the integration of next-generation sequencing (NGS) and metagenomic approaches. Organizations like Illumina are actively developing workflows and reagent kits optimized for wildlife sample matrices, enabling unbiased detection and genomic characterization of POWV with high sensitivity. These developments are anticipated to facilitate real-time outbreak tracking and genomic epidemiology, crucial for understanding virus evolution and transmission dynamics in avian reservoirs.

Digitalization is also reshaping the diagnostics ecosystem. Cloud-based data management solutions provided by companies such as QIAGEN and Thermo Fisher Scientific are being integrated into diagnostic workflows, streamlining result interpretation and enabling rapid data sharing with central surveillance networks. This is especially pertinent as regulatory bodies and research consortia establish more standardized reporting frameworks for avian POWV detection.

In the next few years, further disruption is expected from biosensor and CRISPR-based diagnostic technologies. Firms like New England Biolabs are investing in CRISPR diagnostics, which promise rapid, equipment-light detection that could be transformative for field applications in ornithology and wildlife management. Although these platforms are in the early stages for avian-specific applications, pilot deployments are anticipated by 2027, potentially lowering costs and increasing diagnostic reach in under-resourced regions.

Overall, the convergence of portability, multiplexed molecular detection, real-time genomic surveillance, and digital data integration is set to redefine avian POWV diagnostics through 2030. The sector will likely see increased collaboration between instrument manufacturers, wildlife health agencies, and regulatory authorities to ensure that technological advancements translate into practical, scalable surveillance solutions.

Sources & References

• Thermo Fisher Scientific
• QIAGEN
• Promega Corporation
• Roche
• Centers for Disease Control and Prevention
• IDEXX Laboratories
• Illumina
• Cepheid
• Canadian Food Inspection Agency
• European Medicines Agency (EMA)
• European Food Safety Authority (EFSA)
• IDEXX Laboratories
• Thermo Fisher Scientific
• QIAGEN
• Public Health Agency of Canada
• European Centre for Disease Prevention and Control
• Sysmex Corporation
• FUJIFILM Holdings